UroGen Pharma (URGN) Interest & Investment Income (2017 - 2026)
UroGen Pharma's (URGN) quarterly Interest & Investment Income came in at $608000.0 in Q1 2026, down 71.24% YoY from $2.1 million in Q1 2025, and down 32.67% on a QoQ basis from $903000.0 in Q4 2025.
UroGen Pharma (URGN) Interest & Investment Income (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Interest & Investment Income data on file, last reported at $608000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 71.24% year-over-year to $608000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 58.68% YoY) and the FY2025 annual result came in at $5.3 million, down 38.94% from the prior year.
- Interest & Investment Income slipped to $608000.0 in Q1 2026, from $903000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $2.8 million in Q4 2024 to a low of -$44000.0 in Q1 2022.
- A 5-year average of $1.1 million and a median of $906000.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 1930.0% — and 2026, when it sank 71.24%.
- Tracing URGN's Interest & Investment Income over 5 years: stood at $406000.0 in 2022, then surged by 278.82% to $1.5 million in 2023, then soared by 78.8% to $2.8 million in 2024, then slumped by 67.16% to $903000.0 in 2025, then tumbled by 32.67% to $608000.0 in 2026.
- The last three Interest & Investment Income figures came in at $608000.0 (Q1 2026), $903000.0 (Q4 2025), and $979000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 599,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 599,000.00 |
| Mar 31, 2026 | 608,000.00 |
| Dec 31, 2025 | 903,000.00 |
| Sep 30, 2025 | 979,000.00 |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Sep 30, 2024 | 2.60 Mn |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | 1.54 Mn |
| Sep 30, 2023 | 906,000.00 |
| Jun 30, 2023 | 405,000.00 |
| Mar 31, 2023 | 630,000.00 |
| Dec 31, 2022 | 406,000.00 |
| Sep 30, 2022 | 478,000.00 |
| Jun 30, 2022 | 128,000.00 |
| Mar 31, 2022 | -44,000.00 |
| Dec 31, 2021 | 20,000.00 |
| Sep 30, 2021 | 57,000.00 |